New blood thinner tested for COVID-19 clot prevention
NCT ID NCT07134738
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study looked at whether a drug called Dimolegin can safely prevent blood clots in adults hospitalized with moderate COVID-19. A total of 184 participants took a 60 mg tablet once daily as part of their regular care. The main goal was to check for serious bleeding and other side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Dimolegin (oral tablet, 60 mg once daily)
What this could lead to
If results are positive, Dimolegin could offer a new option to prevent dangerous blood clots in hospitalized COVID-19 patients.
What could go wrong
This was a small, non-interventional study without a comparison group, so it cannot prove effectiveness. The main risk was bleeding, which was closely monitored.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Infectious Diseases Clinical Hospital No. 1
Moscow, Russia
-
Infectious Diseases Hospital No. 2
Sochi, Russia
-
Regional Clinical Hospital No. 3
Chelyabinsk, Russia
-
Regional Infectious Diseases Clinical Hospital
Yaroslavl, Russia
-
Republican Clinical Hospital named after Professor A.F. Agafonov
Kazan', Russia
-
Tomsk Regional Hospital
Tomsk, Russia